论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Qian B, Yang Y, Yao Y, Liao Y, Lin Y
Received 15 January 2018
Accepted for publication 1 March 2018
Published 6 April 2018 Volume 2018:12 Pages 769—776
DOI https://doi.org/10.2147/DDDT.S162577
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Palas Chanda
Peer reviewer comments 2
Editor who approved publication: Dr Tuo Deng
Purpose: Sevoflurane preconditioning (SPC) can provide myocardial protective
effects similar to ischemic preconditioning. However, the exact mechanism of
SPC remains unclear. Previous studies indicate that vascular endothelial growth
factor receptor 1 (VEGFR-1) is involved in ischemic preconditioning-mediated
cardioprotection. This study was designed to determine the significance of
VEGFR-1 signaling in SPC-mediated cardioprotection.
Materials and
methods: Myocardial ischemia–reperfusion
(I/R) rat model was established using the Langendorff isolated heart perfusion
apparatus. Additionally, after 15 min of baseline equilibration, the isolated
hearts were pretreated with 2.5% sevoflurane, 2.5% sevoflurane+MF1 10 µmol/L,
or 2.5% sevoflurane+placental growth factor 10 µmol/L, and then subjected to 30
min of global ischemia and 120 min of reperfusion. The changes in hemodynamic
parameters, myocardial infarct size, and the levels of creatine kinase-MB,
lactate dehydrogenase, cardiac troponin-I, tumor necrosis factor-α, and
interleukin 6 in the myocardium were evaluated.
Results: Compared to the I/R group, pretreatment with 2.5% sevoflurane
significantly improved the cardiac function, limited myocardial infarct size,
reduced cardiac enzyme release, upregulated VEGFR-1 expression, and decreased
inflammation. In addition, the selective VEGFR-1 agonist, placental growth
factor, did not enhance the cardioprotection and anti-inflammation effects of
sevoflurane, while the specific VEGFR-1 inhibitor, MF1, completely reversed
these effects.
Conclusion: Our data have demonstrated that 2.5% sevoflurane preconditioning
alleviates heart I/R injury, which is probably mediated by the
anti-inflammatory property and upregulation of VEGFR-1.
Keywords: sevoflurane, preconditioning, ischemic–reperfusion injury, vascular
endothelial growth factor receptor 1, anti-inflammatory